Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Inclusion criteria:

* A confirmed diagnosis of indolent non-Hodgkin lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia
* Evaluable disease or measurable disease
* Transfusion independent
* Able to take oral medication
* Male and Female subjects \> 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Women of childbearing potential using adequate contraception

Exclusion criteria:

* Prior therapy with a PI3K, mTOR or dual PI3K/mTOR inhibitor resulting in adverse events necessitating treatment discontinuation
* Eligible for a hematopoietic stem cell transplant (HSCT)
* The subject has received investigational or non-investigational cytotoxic chemotherapy (i.e., cyclophosphamide), small molecule cancer therapy (i.e., imatinib), biologic cancer therapies other than rituximab (i.e., alemtuzumab, cytokines, vaccines or other monoclonal antibodies) hormonal therapy, radio- or immuno- conjugates (e.g. ibritumomab tiuxetan, tositumomab) or immunosuppressants to treat malignancy within 4 weeks prior to Cycle 1, Day 1
* Radiation therapy within 2 weeks prior to Cycle 1, Day 1
* Autologous Hematopoietic Stem Cell Transplant (HSCT) within the past 16 weeks
* Prior allogeneic HSCT
* Active central nervous system (CNS) metastases or leptomeningeal involvement
* Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (anti-HCV)
* Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection
* Active peptic ulcer disease requiring treatment with proton pump inhibitors (e.g. pantoprazole) or Type 2 histamine antagonists (e.g. cimetidine)
* Diagnosis or treatment for another malignancy within 3 years of enrollment with the exception of complete resection of basal cell or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy
* Inadequate bone marrow function
* Abnormal liver function
* Abnormal renal function
* Abnormal coagulation

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.